



Resignation of Director

Melbourne, 23 October 2014: The Board of Imugene Limited (Company) announces the resignation of Dr. Nicholas Ede as a Director of the Company. Dr. Ede will continue to be employed by the Company as its Head of Manufacturing and Operations. Dr Ede will assume key operational responsibilities including the management of the manufacturing of Her-Vaxx, oversight of preclinical HER-Vaxx development as well as a range of other day to day operational responsibilities.

“Dr Ede has played a key role in the Company’s transition to an immuno-oncology company and I would like to acknowledge the Board’s appreciation of his outstanding contribution to date,” said Paul Hopper, Executive Chairman of Imugene. “We look forward to Nick’s continued contribution to Imugene as we gear up to begin our Phase I/II clinical trial next year,” Mr Hopper added.

The intention of Dr. Ede to resign as a director of the Company, following the anticipated appointment of a CEO by the Company, was announced in July 2014. Accordingly, following the recent appointment of Charles Walker as CEO, Dr. Ede has resigned as a Director effective 23 October 2014.

Please see attached Final Director’s Interest Notice (Appendix 3Z).

Contact :

Charles Walker
Chief Executive Officer
+61 450 446 990
cwalker[at]imugene.com

Paul A Hopper
Executive Chairman
+1 858 334 5820 (US)
+61 406 671 515 (Australia)
receptogen[at]earthlink.net

Media contact:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 +ve gastric and breast cancer immunotherapies. The Company’s lead product is HER-Vaxx, a proprietary HER2 +ve cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase Ib/II study in gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: IMUGENE LIMITED
ACN: 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Nicholas Ede
Date of last notice	17/4/14
Date that director ceased to be director	23/10/14

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities 655,556 Ordinary Shares.

+ See chapter 19 for defined terms.

Appendix 3Z
Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest. Director related entity	10,000,000 Ordinary Shares.

Part 3 – Director's interests in contracts

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.